Three years after enrolling its first patients, a consortium of researchers examining the growing issue of immune-related adverse events due to immune checkpoint inhibitor cancer therapy released a ...

This Research Topic is Volume II of a series. The previous volume, which has attracted over 21k views can be found here: New Tumor Immune Checkpoints and ...

Please provide your email address to receive an email when new articles are posted on . Education about immune-related adverse events associated with checkpoint inhibitor therapy for cancer is ...

The GINECO window-of-opportunity COLIBRI (NCT04256213) study provides compelling evidence that a neoadjuvant "priming" dose ...

According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published in Nature Medicine, the novel monoclonal antibody linavonkibart has demonstrated the ...

Use of Ablative Radiotherapy in the Setting of Oligometastatic Disease A retrospective analysis of 3,626 patients treated with ICIs for various malignancies within a single health system was conducted ...

Cancer immunotherapy has historically focused on harnessing the ability of T cells to recognize and attack cancer cells. Adaptive immune checkpoint inhibitors (ICIs) unleash tumor-infiltrating ...

UF Health Cancer Institute researchers have discovered a small compound produced naturally by gut bacteria that doubled the response to lung cancer immunotherapy treatment in mice and can now be made ...